Neurocrine Biosciences, Inc.
NBIX
주식 순위
#1573
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the... Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
주가
$135.96
마지막 동기화: 2026-10-16
시가총액
$13.82B
변동 (1일)
-0.72%
변동 (1년)
-2.95%
국가
US
거래 Neurocrine Biosciences, Inc. (NBIX)
카테고리
Healthcare
Neurocrine Biosciences, Inc. (NBIX)의 영업이익률
October 2026 기준 영업이익률 TTM: 23.38%
Neurocrine Biosciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 23.38%입니다. 2023년 말 기준 영업이익률은 13.30%였습니다.
Neurocrine Biosciences, Inc.의 영업이익률 기록 (2000 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 23.38% | -3.47% |
| 2024 | 24.22% | 82.11% |
| 2023 | 13.30% | -20.50% |
| 2022 | 16.73% | 85.07% |
| 2021 | 9.04% | -41.98% |
| 2020 | 15.58% | 69.90% |
| 2019 | 9.17% | 12.38% |
| 2018 | 8.16% | -110.04% |
| 2017 | -81.27% | -91.73% |
| 2016 | -982.48% | 106.18% |
| 2015 | -476.51% | 0.00% |
| 2014 | 0.00% | -100.00% |
| 2013 | -1,701.88% | -62,669.12% |
| 2012 | 2.72% | -93.79% |
| 2011 | 43.82% | -206.98% |
| 2010 | -40.96% | -97.75% |
| 2009 | -1,817.47% | -17.24% |
| 2008 | -2,196.18% | -87.33% |
| 2007 | -17,340.03% | 5,903.75% |
| 2006 | -288.82% | 1,326.98% |
| 2005 | -20.24% | -67.06% |
| 2004 | -61.44% | 45.35% |
| 2003 | -42.27% | -92.64% |
| 2002 | -574.20% | 439.66% |
| 2001 | -106.40% | -56.40% |
| 2000 | -244.04% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 38.59% | -98.35% |
US
|
|
| -149.01% | -106.37% |
US
|
|
| 25.57% | -98.91% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -98.77% |
NL
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.